New Laser Portfolio and Most Powerful Urological Laser
July 12, 2018
Dornier MedTech Introduces New Laser Portfolio and Most Powerful Urological Laser for Stone Lithotripsy in Singapore
Singapore, 12 July 2018 – Dornier MedTech (Dornier), a global leader in innovative kidney stone management, today announced the introduction in Singapore a new laser portfolio comprising of Dornier Medilas® H Solvo® 35 and Dornier Medilas® H 140 for the treatment of urological stones and benign prostate hyperplasia, at the annual Asia Pacific UroFair 2018 taking placing at Grand Hyatt, Singapore, 12-14 July 2018.
The Dornier Medilas® H Solvo® 35 and Dornier Medilas® H 140 are the new generation of holmium lasers that aim to improve workflow efficiency in the operating room. They are the latest additions to Dornier’s portfolio of market-leading holmium laser brands. The products have received US FDA certification and CE Mark and are now commercially available in Europe and the US.
The H Solvo 35 is a 35-watt holmium laser that integrates Dornier’s patented Advanced Mode™ technology designed to reduce stone retropulsion. Physicians can now break and dust kidney stones more efficiently. Stone retropulsion or the migration of stones is a common occurrence in stone lithotripsy procedures that often results in increased operative cost and time.
The H 140 is a high-power device that is the fastest and most powerful holmium laser in the market. Its high frequency allows for precise, fast class dusting and cutting procedures. It is also the only device to integrate an optional morcellation module that enables streamlined and economical benign prostatic hyperplasia treatments.
Singapore will be the first market in Asia for Dornier MedTech’s debut of the H Solvo 35 and H 140. Dornier MedTech is a market leader in the region, where majority of urologists rely on its trusted products since 1983 to deliver treatments to their patients. Incidence of stone disease in Asia is rapidly growing in parallel with the rising rates of obesity and diabetes. In Singapore, about 15% of the population has kidney stone disease. Recurrence occurs in almost 25% to 50% of all cases2.
Abel Ang, President and CEO of Dornier MedTech said: “The Dornier Medilas H Solvo 35 and H 140 are the results of extensive customer research and our commitment to innovation, and we are proud to add them to our expanding portfolio of market leading patented lasers and fibres to meet the needs of a growing market for non-invasive urology surgery. The versatility and unique technology of H Solvo 35 and H 140 can be applied across a variety of stones, enhancing clinical practice and enabling urologists and clinicians achieve better results for their patients.”
Dornier MedTech will exhibit Dornier Medilas H Solvo 35 and Dornier Medilas H 140 at booth A10 at the UroFair 2018.
Emma Thompson/ Stephanie Tan
+65 6340 7287
About Dornier MedTech
Dornier MedTech is headquartered in Munich, Germany, and is a full subsidiary of Accuron MedTech. Dornier is a medical device company focused on providing leading technology and improving life by delivering scientifically superior products and solutions to physicians, healthcare providers and research groups involved in urological care. As pioneers of the lithotripsy and a variety of surgical lasers, Dornier’s 40 years of innovation and service has made it one of the most trusted MedTech companies in the industry.
Dornier Medilas® is a registered trademark of Dornier MedTech GmbH. The Dornier Medilas H Solvo 35 and H 140 are currently undergoing registration approvals in Asia.
 Strittmatter, F, et al. Does the laser pulse shape influence the treatment of stones? Poster presentation at 2018 American Urological Association Annual Meeting.
 Dornier MedTech
 Atul Sohgaura and Papiya Bigoniya, 2017. A Review on Epidemiology and Etiology of Renal Stone. American Journal of Drug Discovery and Development, 7: 54-62.
 Tan Tock Seng Hospital. Preventing kidney stones.